LGVN: 49% | Longeveron Announced Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B In Mild Alzheimer's Disease; Study Meets Its Key Objectives To Advance Data Supporting Favorable Benefit/Risk Profile
PHG: 11% | Koninklijke Philips Q2 2024 Adj EPS €0.30 Beats €0.25 Estimate, Sales €4.462B Beat €4.430B Estimate
LIPO: 204% | Lipella Pharmaceuticals Commences Phase 2a Trial For LP-310 In Oral Lichen Planus, Enrolls First Patients